Biomedical subjects

O M Van Duyn

Publications and source records attributed to O M Van Duyn.

3 recordsLinked to original sources

PubMed1994

Concurrent ceftazidime DUE with clinical pharmacy intervention.

Ceftazidime use at our institution, a 580-bed county teaching hospital, has steadily increased since its addition to the formulary in 1986. In response to this increased use and because the institutional antibiogram showed increased resistance by Pseudomonas aeruginosa (from 10 to 28% resistant), the P & T Committee requested that a drug use evaluation (DUE) of ceftazidime be conducted. Analysis of this retrospective pilot study showed that 87% of ceftazidime use was inappropriate. To further evaluate ceftazidime use, to identify problems not assessed during retrospective review, and to correct problems while patients were receiving the drug, a concurrent ceftazidime use evaluation was conducted. The methods and results of the concurrent review are presented below.

Ceftazidime↗

PubMed1982

Evaluation of four assay methods for determination of tobramycin in human serum.

Four assay procedures for tobramycin in serum--enzyme immunoassay (I), substrate-labeled fluorescent immunoassay (II), radioimmunoassay (III), and bioassay (IV)--were compared and evaluated by replicate and analytical recovery studies. I and II were about 50% more precise than III and IV. II was substantially more nearly accurate than the other methods and also gave the best reproducibility (correlation coefficient 0.992 between-day). The least expensive method was IV. Ease of handling favored I and II. Overall, we find II to be the most acceptable procedure for use in the clinical laboratory.

Anti-Bacterial Agents↗

PubMedDate not supplied

Comparison of gentamicin bioassay values utilizing three different indicator organisms.

Gentamicin serum concentrations were monitored via bioassay with three indicators, to determine if assay results were influenced by the testing organism. When mean assay values, from seven samples, were compared to mean target values, there was no significant differences with Staphylococcus epidermidis, Bacillus subtilis or Klebsiella pneumoniae. However, levels from one of the seven samples yield dramatically lower concentrations, for all three indicators, than the target. This suggests the presence of a bioassay inhibitor substance. Additional testing of the organisms, versus serum without gentamicin, revealed Bacillus subtilis to be much more serum-sensitive than the others.

Bacillus subtilis↗